Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.   4 January 2022
Medtech
Medical devices company InfoBionic has argued that it should be awarded nearly $2.9 million in fees for attorneys, expenses and expert witnesses.   23 December 2021
Big Pharma
Oxfam America has filed a complaint with the US Securities and Exchange Commission (SEC) claiming that Moderna failed to inform investors that it was in a dispute with the National Institutes of Health over a COVID–19 vaccine patent.   23 December 2021
Big Pharma
Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.   22 December 2021
Biotechnology
AbbVie seeks to block imports of Alvotech’s biosimilar Humira into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.   21 December 2021
Americas
Apotex has asked the US Supreme Court to reconsider a US Court of Appeals for the Federal Circuit ruling upholding four of Teva Pharmaceutical’s cancer drug patents.   21 December 2021
Americas
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.   21 December 2021
Biotechnology
Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.   16 December 2021
Generics
Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.   16 December 2021
article
The Unified Patent Court is set to open in 2022 and has the potential to significantly change how patents are applied for and protected in Europe. The Bundesrat has approved the Protocol on Provisional Application of the UPC Agreement, taking us another step closer. The Protocol on Provisional Application is not yet in force, it needs to be ratified by one further EU state which now looks set to be Austria.   16 December 2021